Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor

Executive Summary

• Vector Science & Therapeutics appointed Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board of Directors.
• Valor is a newly formed sports medicine division designed to build a commercial network and distribution channel for Vector's transdermal peptide delivery platform, targeting elite athletes and sports medicine clinicians.
• Drake brings over a decade of experience building high-performance commercial teams and managing relationships with top athlete influencers, positioning him to lead Valor's market entry.

Key Details

• Appointee & Roles: Darryl Drake Jr. appointed as President of Valor and Chairman of the Athletic Board of Directors.
• Division Focus: Valor will initially promote Vector's line of pharmaceutical-grade peptides and establish a network of sports medicine clinicians, trainers, and elite athlete advocates ahead of the Valor transdermal delivery platform's commercial launch.
• Product & Manufacturing: Peptides are manufactured under cGMP standards in an FDA-licensed, state-of-the-art facility in Mequon, Wisconsin, and tested for safety, purity, and potency.
• Therapeutic Target: The platform aims to provide an alternative to systemic pain medicines (including opiates) by focusing on tissue repair, accelerated recovery, and site-directed pain mitigation.
• Appointee Background: Drake is an early investor in Vector with over a decade of experience building high-performance commercial teams across multiple countries, managing relationships with top athlete influencers and multimedia platforms, and driving over $150 million in sales.
• Strategic Mandate: Valor's approach integrates Vector's peptide science with delivery platforms to create a relationship-first, precision delivery model for the professional and elite athlete market.

Notable Quotes

• "Athletes deserve better than systemic pain management and extended recovery timelines. Valor exists to change that, with precision delivery, targeted tissue repair, and solutions built for the way athletes actually heal." -- Darryl Drake Jr., President, Valor
• "Darryl has the relationships, the track record, and the personal conviction this role demands. He is the right person to take Valor to market." -- Bill Jackson, CEO, Vector Science & Therapeutics Corp.